Nowadays, one of the nanobodies that has received the European Medicines Agency (EMA) and the USA Food and Drug Administration (FDA) approval is Caplacizumab which has been designed for treatment of thrombotic thrombocytopenic purpura by targeting the von Willebrand Factor (vWF) (23). Here, VWF is linked to thrombotic thrombocytopenic purpura.